NIH Shopping Peptide Eyedrops to Save Your Vision
Published Date: 7/24/2026
Notice
Summary
The National Eye Institute has a cool new invention using special peptides to help protect eyes from inherited diseases like retinitis pigmentosa, which causes vision loss for over 100,000 Americans. They’re looking for partners to help develop easy-to-use eyedrops or gene therapy to slow down or stop this eye damage. This could bring hope and new treatments to many people with few options, and interested parties can start talking to the NIH now!
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Potential New Treatment for Retinal Degeneration
Researchers developed a 17-amino-acid PEDF peptide (17-mer [H105A]) that showed potent protective effects on photoreceptors in in vivo mouse models. This peptide could be developed as an eyedrop or AAV2 gene-delivery therapy to prevent or slow photoreceptor degeneration in inherited retinal diseases like retinitis pigmentosa (affecting over 100,000 people in the U.S.) and in age-related macular degeneration.
NIH Offering PEDF Licensing Opportunity
The National Eye Institute (NEI) is seeking partners or licensees to co-develop a Pigment Epithelium-Derived Factor (PEDF) peptide therapy using either an AAV2-based delivery system or an eyedrop formulation. The technology is offered with NIH Reference Number E-028-2023 and is available for licensing and co-development now.
Therapy Still at Pre-Clinical Stage
The PEDF peptide technology and delivery approaches are at the pre-clinical development stage (in vivo validation). That means the therapy is not yet approved or available for clinical use while further development is pursued.
Developer Advantage: AAV2 Pathway Similarity
NEI notes the AAV2 vector approach is identical to Luxturna, an FDA-approved retinal therapy, suggesting a partially established regulatory path for developers pursuing an AAV2 delivery route. The notice highlights competitive advantages such as favorable safety profile and lower production costs compared with biologics.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-18191, Submission for OMB Review; 30-Day Comment Request Data and Specimen Hub (DASH) (Eunice Kennedy Shriver National Institute of Child Health and Human Development)
The National Institutes of Health (NIH) is asking for public feedback on their Data and Specimen Hub (DASH), which helps researchers share important health data. This is a quick 30-day review to make sure the information collection is clear and useful. If you’re involved in health research or data sharing, your input by October 8, 2026, can help shape how DASH works without costing extra money or time.
2026-17899, Proposed Collection; 60-Day Comment Request; Assurance (Interinstitutional, Foreign, and Domestic) and Annual Report (Office of the Director)
The NIH wants your thoughts on their plan to keep track of animal research safety through yearly reports and assurances from institutions, both in the U.S. and abroad. This helps make sure labs follow the rules and protect animals, with no new costs or big changes expected. You’ve got until October 2, 2026, to share your feedback and help improve the process!
2026-17687, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in October 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, ensuring fair and confidential decisions. Scientists applying for grants in genetics, molecular sciences, oral health, and cancer research are the ones affected, with no direct cost changes announced.
2026-17438, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings in late September 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers applying for funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
Previous / Next Documents
Previous: 2026-14979, Cboe Clear U.S., LLC; Notice of Filing of an Application, as Amended, for Temporary Registration as a Clearing Agency Under Section 17A of the Securities Exchange Act of 1934
Cboe Clear U.S., LLC wants to become a temporary official clearing agency to handle special financial contracts called binary options. This change affects traders and companies dealing with these contracts by adding a trusted middleman to make sure trades settle smoothly. The SEC is reviewing the application and asking for public feedback before making a final decision.
Next: 2026-14981, Government Owned Invention Available for License: Nucleophosmin 1 (NPM1) Mutation-Specific T Cell Receptors for Targeted Treatment of Acute Myeloid Leukemia (AML)
The government has developed special T cell receptors that can target a tough type of blood cancer called acute myeloid leukemia (AML), especially in patients with a specific genetic marker. These new receptors promise safer, more precise treatment with fewer side effects than current options. Researchers and companies can now license this invention to help bring this exciting therapy to patients faster.